Department of Pharmaceutics Associate Professor Ed Kelly and graduate student Cate Lockhart (UW PharmD, ’13) are undaunted by the challenge of researching the rare blinding eye disease, Bietti’s Crystalline Dystrophy (BCD). “Only one in 70,000 people has the disease and no one is doing basic research on BCD except our lab,” Kelly said. As he’s […]
Read More
Bietti’s Crystalline Dystrophy (BCD) causes small, fatty deposits to accumulate in the back of the eye. These deposits cause gradual degeneration of the photoreceptor cells (rods and cones) and cause other abnormalities in the retina, resulting in mid-life blindness. About a decade ago, Kelly and professor Allan Rettie, a colleague, learned that researchers at the […]
Read More
The U.S. Environmental Protection Agency will provide $6 million in seed funding for a Predictive Toxicology Center at the University of Washington, enabling researchers, including Department of Pharmaceutics Associate Professor Edward Kelly, to develop more accurate in vitro models – organ-mimicking cell cultures – to test chemicals for their potential risk to humans and to help accelerate […]
Read More